A naukri.com initiative
Bioengineer
1w
209
Image Credit: Bioengineer
Ultrapotent Single-Domain Antibodies Clamp SARS Spike
- Researchers have developed ultrapotent single-domain antibodies that neutralize the SARS coronavirus by targeting a vulnerable region on the viral spike protein, preventing infection and overcoming mutation-driven escape mechanisms.
- These antibodies focus on a conserved locus at the spike's base, clamping it to impede viral fusion with host cells, offering potential therapeutics for current and future coronavirus outbreaks.
- Derived from camelids, single-domain antibodies have unique structural stability, enabling them to access hidden epitopes and bind tightly to the spike protein at low concentrations.
- By targeting a more conserved region at the spike's base, these antibodies exhibit broad-spectrum efficacy against different SARS coronavirus strains, showing promise for pan-coronavirus therapeutics.
- Structural biology techniques reveal how the antibodies bind to the spike, preventing the transition to a fusion-active conformation and neutralizing viral infectivity at a molecular level.
- Preclinical models demonstrate the antibodies' efficacy in prophylactic and therapeutic settings, reducing viral loads and disease progression, offering dual functionality in pandemic scenarios.
- These antibodies may also have diagnostic potential, aiding in sensitive detection of coronaviruses in clinical samples to enhance surveillance efforts.
- Challenges remain in humanizing the antibodies, safety profiling, and exploring combination therapies, but their potential as powerful antiviral agents is significant for future pandemic responses.
- This research highlights the importance of interdisciplinary collaboration in developing innovative therapeutics that target viral entry mechanisms to combat pandemic threats effectively.
- The groundbreaking antibodies not only offer a potent tool in neutralizing coronaviruses but also pave the way for transformative solutions with profound health impacts in the ongoing battle against viral pathogens.
Read Full Article
12 Likes
For uninterrupted reading, download the app